Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include; expert opinions on the modification of...

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include; the US Food and Drug Administration (FDA) approval of AstraZeneca’s...

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include; expert opinions on the 12-week Phase II study data published for Prometic’s PBI-4050 as a...

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen’s announcement of positive results from a planned overall survival (OS)...

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent biosimilar launches in the US such as Pfizer’s Inflectra (infliximab-dyyb) and how this has...

Gain new KOL insights on the latest events happening in malignant melanoma (MM), including; data from Prima BioMed’s Phase I TACTI-mel clinical trial programme for IMP321, a first-in-class Antigen Presenting Cell...

Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including; the FDA accepting Merck and Co.’s regulatory filing for Keytruda (pembrolizumab) in combination with...

This edition presents key opinion leader (KOL) views on recent developments in the COPD market. Topics covered include; Novartis’ December 2016 publication of positive results from the CRYSTAL study, which explored...